Jupiter Topco LLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Jupiter Topco LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 9,540,764 shares of the biotechnology company’s stock, valued at approximately $95,268,000. Jupiter Topco LLC owned 3.73% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in BCRX. Elmind Capital LP acquired a new stake in BioCryst Pharmaceuticals during the second quarter valued at $5,200,000,000. ADAR1 Capital Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $1,330,000. Hsbc Holdings PLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $1,079,000. PDT Partners LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $245,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at about $1,158,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.83 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The firm has a market capitalization of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55. The business’s 50 day moving average price is $9.68 and its 200-day moving average price is $9.02.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. During the same period in the prior year, the company earned $0.15 EPS. The firm’s revenue was up 33.6% compared to the same quarter last year. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Analysts Set New Price Targets

BCRX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Royal Bank Of Canada reduced their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Citizens Jmp increased their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.